Published in J Lipid Res on May 13, 2009
Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab (2010) 1.45
Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol (2012) 1.10
From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux. World J Gastroenterol (2010) 0.93
A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends Pharmacol Sci (2015) 0.91
A reappraisal of the mechanism by which plant sterols promote neutral sterol loss in mice. PLoS One (2011) 0.90
A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport. World J Gastroenterol (2010) 0.89
Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice. J Lipid Res (2013) 0.83
Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol (2014) 0.80
Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice. PLoS One (2014) 0.78
Intestinal nuclear receptors in HDL cholesterol metabolism. J Lipid Res (2014) 0.77
Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine. PLoS One (2016) 0.76
Trust your gut: galvanizing nutritional interest in intestinal cholesterol metabolism for protection against cardiovascular diseases. Nutrients (2013) 0.75
Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest (2017) 0.75
Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism. Biochim Biophys Acta (2016) 0.75
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int J Mol Sci (2015) 0.75
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology (1996) 7.92
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell (2003) 6.53
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 6.19
Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol (2004) 5.66
Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 4.95
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A (2001) 4.22
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A (2003) 4.03
The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J (1992) 3.92
Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A (2001) 3.58
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol (2003) 3.26
PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol (1995) 3.14
Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J Clin Invest (2002) 3.13
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest (2007) 3.01
The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A (1994) 3.00
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab (2008) 2.84
Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol (1996) 2.48
Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res (1978) 2.37
Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem (1994) 2.20
Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem (1995) 1.88
Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology (2007) 1.69
The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis (2005) 1.55
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol (2006) 1.50
Rab8-dependent recycling promotes endosomal cholesterol removal in normal and sphingolipidosis cells. Mol Biol Cell (2006) 1.32
Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res (2004) 1.26
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.26
Enzymatic measurement of choline-containing phospholipids in bile. J Lipid Res (1981) 1.24
High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem (2004) 1.21
Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.17
Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage. FASEB J (2005) 1.12
Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta (2007) 1.09
Fluorometric enzymatic determination of total cholesterol in serum. Clin Chem (1975) 1.09
Megalin and cubilin expression in gallbladder epithelium and regulation by bile acids. J Lipid Res (2004) 0.94
Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res (2006) 0.88
PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol Sci (2008) 0.86
Cloning of novel members of the steroid hormone receptor superfamily. J Steroid Biochem Mol Biol (1991) 0.85
Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol Cell Biol (1992) 0.83
Gas-liquid chromatography of fecal neutral steriods. J Chromatogr (1977) 0.77
Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 6.04
Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev (2009) 5.11
The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem (2005) 3.51
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res (2013) 2.67
Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem (2002) 2.61
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest (2006) 2.55
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (2002) 2.39
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest (2012) 2.33
Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology (2014) 2.19
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology (2010) 2.16
Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology (2008) 2.06
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes (2007) 2.01
ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology (2008) 1.95
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol (2005) 1.84
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem (2004) 1.81
Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.80
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
β₂-glycoprotein I: a novel component of innate immunity. Blood (2011) 1.75
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol (2005) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology (2006) 1.71
Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem (2009) 1.71
HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol (2005) 1.70
Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology (2007) 1.69
Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology (2003) 1.64
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol (2003) 1.61
Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem (2003) 1.61
New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr Opin Lipidol (2006) 1.58
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol (2004) 1.58
LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J Clin Invest (2012) 1.58
Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol (2011) 1.57
Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol (2007) 1.55
Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. Pediatr Res (2007) 1.54
Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology (2006) 1.51
High fat feeding induces hepatic fatty acid elongation in mice. PLoS One (2009) 1.51
Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem (2002) 1.50
Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology (2005) 1.50
Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem (2003) 1.45
Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 1.44
Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol (2002) 1.43
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis (2005) 1.41
Transintestinal cholesterol efflux. Curr Opin Lipidol (2010) 1.39
Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem (2009) 1.38
Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology (2004) 1.36
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res (2005) 1.35
Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs (2007) 1.34
Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol (2005) 1.34
Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun (2002) 1.32
A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.30
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res (2006) 1.28
Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res (2008) 1.28
Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology (2006) 1.28
A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med (2004) 1.28
Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes (2003) 1.28
24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem (2006) 1.28
Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res (2004) 1.26
Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells. Cell (2013) 1.25
Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol (2006) 1.23
Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res (2006) 1.22
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett (2005) 1.21
Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest (2010) 1.20
Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatology (2009) 1.20
Accelerated lipid absorption in mice overexpressing intestinal SR-BI. J Biol Chem (2006) 1.19
The liver X-receptor gene promoter is hypermethylated in a mouse model of prenatal protein restriction. Am J Physiol Regul Integr Comp Physiol (2009) 1.18
Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther (2004) 1.18
Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.17
Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab (2005) 1.16
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun (2005) 1.16
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol (2009) 1.16